UNION therapeutics completes 62 million DKK private placement to support clinical program
Hellerup, Denmark, 1 December 2022 – UNION therapeutics A/S (UNION), a privately-held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious diseases, today announced the completion of a […]
UNION therapeutics to present at the 6th Annual Dermatology Drug Development Summit
Data on pharmacological properties of orismilast to be presented on 2nd of November 2022 Orismilast is a potent next-generation PDE4 inhibitor with broad anti-inflammatory properties in development as a first-in-class […]
UNION therapeutics presents new data on orismilast at the 31st EADV Congress supporting orismilast’s potential as a first-in-class or best-in-class treatment for certain immunological diseases
Preclinical data presented in the oral presentation demonstrate that orismilast is a potent inhibitor of phosphodiesterase type-4 (PDE4), and that orismilast more selectively inhibit PDE4B and PDE4D subtypes which are […]
UNION therapeutics announces regulatory approval of Treatment Extension for the ongoing OSIRIS Phase 2a open label study with orismilast MR tablet for patients with Hidradenitis Suppurativa (HS)
OSIRIS is an investigator-initiated Phase 2a open label study, studying orismilast modified release (MR) tablet as a potential treatment for HS Treatment Extension gives the possibility to allow patients to […]
UNION therapeutics announces presentation of new data on orismilast at the 31st EADV Congress
Oral presentation of new preclinical data on pharmacological properties of orismilast at the EADV Congress Additional e-poster details the safety and efficacy of orismilast IR (immediate release) tablets in adults […]
UNION therapeutics completes patient enrollment in the IASOS Phase 2b study of orismilast MR tablet in patients with psoriasis
Topline results expected in first half of 2023 Orismilast is a potent next generation PDE4 inhibitor with broad anti-inflammatory properties also in development for the treatment of hidradenitis suppurativa (HS) […]
UNION therapeutics announces expansion to India of the PROTECT-V Phase 2/3 study of niclosamide nasal spray as COVID-19 prophylaxis
The PROTECT-V Phase 2/3 platform study investigating niclosamide nasal spray as prophylactic treatment for COVID-19 in kidney patients will now be conducted in both the UK and India UK investigators […]
The PROTECT-V trial investigating UNIONs COVID-19 candidate receives Urgent Public Health Prioritization from the UK government
Hellerup, Denmark, March 29, 2021 – UNION therapeutics A/S (UNION) today announced that the National Institute for Health Research (NIHR) in the UK has granted Urgent Public Health (UPH) prioritization to […]
UNION’s nasal spray for COVID-19 enters a 1,500 high-risk patient study
UNI91103 is a nasal spray delivering niclosamide – a potent inhibitor of SARS-CoV-2 with in-vitro potency >40x higher than remdesivir – to the nasal cavity UNI91103 has been selected as […]
UNION Completes Over-subscribed 155m DKK Equity Capital Raise to Accelerate Clinical Programs
Hellerup, Denmark, February 9, 2021 – UNION therapeutics A/S (“UNION”), a privately held, clinical stage pharmaceutical company, today announced the completion of a 155m DKK financing round from a group […]
